Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer

S. von Itzstein, Mitchell; F. Burns, Timothy; E. Dowell, Jonathan; Horn, Leora; Ross Camidge, D.; J. York, Sally; D. Eaton, Keith; Kyle, Kelly; Fattah, Farjana; Liu, Jialiang; Mu-Mosley, Hong; Gupta, Arjun; Nadeem, Urooba; Gao, Ang; Zhang, Song; E. Gerber, David

doi:10.1158/1078-0432.ccr-24-1722

Public

Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS -Mutant Non–Small Cell Lung Cancer

Published in Clinical Cancer Research • Dec 9, 2024

Authors:

Mitchell S. von Itzstein

Timothy F. Burns

Jonathan E. Dowell

Abstract

PURPOSE: Patients with Kirsten rat sarcoma viral oncogene (KRAS)-mutant non-small cell lung cancer (NSCLC) have limited therapeutic options. Based on the activity of nuclear export inhibition in preclinical models, we evaluated this strategy in previously treated, advanced KRAS-mutant NSCLC. PATIENT...

Subject

Docetaxel

Medicine

KRAS

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!